1 / 22

Read the SMALL PRINT of the 1572

The Essential GCP Document. Read the SMALL PRINT of the 1572. Good Clinical Practice (GCP). A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that

channery-wong
Download Presentation

Read the SMALL PRINT of the 1572

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Essential GCP Document Read the SMALL PRINTof the 1572

  2. Good Clinical Practice (GCP) • A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that • the Data and Reported Results are Credible, and Accurate, • and that • the Rights, Integrity, and Confidentiality of Trial Subjects are Protected. = Quality Data = Ethics Quality Data + Ethics = GCP

  3. Obligations of Investigators Video A “GCP Day” in the life of a clinical researcher

  4. GCPs: Discussion • What “ethics” process was shown in the video? • the Rights, Integrity, and Confidentiality of Trial Subjects are Protected. • What “data quality” concepts were shown? • the Data and Reported Results are Credible, and Accurate

  5. Form FDA 1572: It’s the Law! • 21 Code of Federal Regulations 312.53 (c) (1) • Before permitting an investigator to begin participation in an investigation, the sponsor shall obtain the following: • A signed investigator statement (Form FDA-1572)

  6. Form FDA 1572: Location • DHHS’s Program Support Center (PSC): http://forms.psc.gov/ • Click on “FDA” for currentversion of 1572 (and instructions) • Note: In last year there have been 3 versions • Sep 30, 2002 • Nov 30, 2002 • Jan 31, 2006

  7. Expiry Date Investigator Information Education, Training, and Experience Study Location Laboratory Information IRB Information List of Subinvestigators

  8. Bioresearch Monitoring Information System File (BMIS) • http://www.fda.gov/oc/gcp/clinenforce.html • Abstracts IND study information from 1572 and other documents • Contains information on: • Investigators • Contract Research Organizations (CROs) • Institutional Review Boards (IRBs) • Lists separate information entry each time a new IND is submitted

  9. Expiry Date Investigator Information Education, Training, and Experience Study Location Laboratory Information IRB Information List of Subinvestigators Protocol/IND Number (Sponsor Information)

  10. IND Requirement • Investigational New Drug [21CFR312.3] • New drug, or • New biological drug • New biological product used in vitro for diagnostic purposes • Phase 1, 2, or 3 studies • Administered or dispensed to, or used in, one or more human subjects

  11. Clinical Phase Commitments • S • M • A • L • L • P • R • I • N • T Filing Instructions Investigator Signature and Date

  12. 1572 Commitments: Box 9 • S _______ • M ______ ______ • A _____ to _______ • L ____ __________ ________ • L etFDA Inspect • __P__ _______ _______ • R etainRecords • I _____ _______ • N ____ _ _ _ • T ____ ______

  13. 1572 Commitments: Box 9 upervise • S _______ • M ______ ______ • A _____ to _______ • L ____ __________ ________ • L etFDA Inspect • __P__ _______ _______ • R etainRecords • I _____ _______ • N ____ _ _ _ • T ____ ______ aintain Records dhere Protocol earn Investigator’s Brochure Re ort Adverse Events nform Subjects otify I R B rain Staff

  14. DataQuality PeopleNeeds Ethics 1572 Commitments: Box 9 upervise • S _______ • M ______ ______ • A _____ to _______ • L ____ __________ ________ • L etFDA Inspect • __P__ _______ _______ • R etainRecords • I _____ _______ • N ____ _ _ _ • T ____ ______ aintain Records dhere Protocol earn Investigator’s Brochure Re ort Adverse Events nform Subjects otify I R B rain Staff

  15. 1572: Discussion Points • For what studies is the 1572 used? • Who can be the investigator (i.e. signatory)? • Who can be a sub investigator (Box 6)?

  16. 1572 Problem Cases

  17. FDA Warning Letters (WL) • A post FDA inspection document • An informal advisory to a firm communicating FDA's position on a matter but does not commit FDA to taking enforcement action • http://www.fda.gov/oc/gcp/clinenforce.html

  18. WL (5 Jun 02): Hassman, MD • The investigator agreement you signed requires you to personally conduct or supervise the clinical investigation (see FDA Form 1572). • FDA’s investigation revealed that you failed to adequately supervise those aspects of clinical investigations which you did not personally conduct. As described in more detail …, this lack of supervision resulted in submission of false information to the sponsor and failure to maintain adequate and accurate case histories.

  19. WL(17 Apr 02): Yu, MD, PhD • “You failed to obtain a signed investigator statement, Form FDA 1572 • from all investigators prior to permitting them to begin participation in the investigation.” • “You failed to provide a complete list of the sub-investigators • who assisted you in the conduct of the investigation.”

  20. FDA Problem Investigators Lists • Restricted List • Names of all clinical investigators who have agreed to certain restrictions with respect to their conduct of clinical investigations • http://www.fda.gov/ora/compliance_ref/bimo/restlist.htm

  21. Restrictions List: Cases

  22. 15 2 “The obligations of the 1572 must be applied to all clinical research." Anonymous

More Related